Introduction
============

Type 1 diabetes mellitus requires continual intensive treatment in order to reduce the risk and progression of chronic micro- and macro-vascular complications.[@b1-ppa-7-867] On the other hand, the treatment of the condition is associated with a high risk of acute complications, particularly hypoglycemia.[@b2-ppa-7-867] The prevention and control of both types of complications are significantly influenced by adherence to treatment. The multiple lifestyle modifications that are of utmost importance in the management of diabetes require a high degree adherence from the patients as well.[@b3-ppa-7-867]

Adherence is defined as the extent to which a person's behavior (taking medication, making lifestyle modifications) corresponds with the agreed recommendations from a health care provider.[@b4-ppa-7-867] Adherence to the treatment of chronic diseases is customarily poor and as such negatively influences both effectiveness in routine clinical practice as well as the efficacy outcomes of various therapeutic methods in clinical trials.[@b5-ppa-7-867]--[@b9-ppa-7-867] The correlations between adherence and clinical outcomes of patients with both types of diabetes were analyzed in one review article[@b10-ppa-7-867] which, like another study,[@b3-ppa-7-867] has shown the positive effect of adherence on metabolic control in adults with type 1 diabetes.

A number of factors affecting adherence to treatment in different clinical situations have been identified. To promote adherence in routine clinical practice, those intuitive, unambiguously detectable and closely associated with attitudes toward treatment are of key relevance. One of the most suggestible factors influencing adherence may be treatment satisfaction.[@b11-ppa-7-867]

Since positive correlates in one population may represent negative ones in other populations,[@b7-ppa-7-867] it is important to study the relation in a specific clinical context. Little attention has as of yet been devoted to adherence regarding the treatment of type 1 diabetes. To our knowledge, the possible association between adherence and socio-demographic and/or clinical characteristics based on observational data taken from routine practice and attitudinal factors has not yet been adequately investigated in adults with type 1 diabetes. The available studies are related mainly to children and adolescents,[@b12-ppa-7-867]--[@b15-ppa-7-867] with a number of these[@b14-ppa-7-867],[@b15-ppa-7-867] suggesting certain positive, especially psychological, correlates of higher adherence. Kyngäs and Rissanen[@b14-ppa-7-867],[@b15-ppa-7-867] have stated that support from health care providers and relatives as well as overall motivation, willpower, and threat to the physical wellbeing of the patient were predictors of good adherence. These results, however, cannot be generalized to adult patients with type 1 diabetes, as adherence may vary during the lifetime depending on the formation of the personality, including the attitude towards treatment.[@b16-ppa-7-867] The previously mentioned review[@b11-ppa-7-867] dealing with the relationship between adherence and treatment satisfaction included only one study with type 1 diabetes, and, further, this was not conducted in adults only and used a non-validated questionnaire to assess satisfaction. Consequently, we feel that the relationship between adherence and treatment satisfaction in adults with type 1 diabetes merits further investigation.

With reference to type 1 diabetes management, the term adherence is now often specified by the expressions self-care adherence or self-management adherence to correspond better with the comprehensive nature of the tasks to be mastered by the patient on an everyday basis in order to control the disease and to reach therapeutic goals.[@b17-ppa-7-867],[@b18-ppa-7-867]

Overall, the aim of this study was to analyze adherence to self-care recommendations and to identify specific correlates in patients with this condition. The results of investigations into these relationships could aid healthcare providers in the estimation of the adherence of their patients. Those with potentially lower adherence might be provided with additional support specifically tailored to individual needs, the effect of which could improve treatment outcomes.

Methods
=======

An observational cross-sectional study was conducted in the Diabetes Center of the University Hospital in Hradec Králové, Czech Republic, from September to December 2010. The study design was approved by the regional Ethics Committee and conforms to the provisions of the Declaration of Helsinki.

Study population
----------------

On randomly selected days, all patients with type 1 diabetes who had appointments at the outpatient clinic of the Diabetes Center were addressed, and those who met the entry criteria, agreed to fill out the questionnaire and were willing to provide their informed consent to use their medical records were enrolled in the study. The entry criteria were as follows:

1.  Age ≥18 years;

2.  partaking in continuous subcutaneous insulin infusion (CSII) therapy or multiple daily injections (MDI) therapy for ≥last 12 months;

3.  in females, no pregnancy during the last 12 months;

4.  no acute comorbidity.

MDI therapy was defined as three or more daily insulin injections.

Of 132 (100%) patients addressed, 123 (93%) agreed to participate in the study. Twelve of these were excluded from the study due to a failure to meet the entry criteria, thus a total of 111 (84%) patients were enrolled.

Questionnaires
--------------

Questionnaires were self-administered by previously instructed patients during routine follow-up visits to the Diabetes Center. To collect the basic socio-demographic data and health and clinical characteristics, two different versions of the questionnaire were used, one for the patients on CSII and another for those on MDI therapy. The following two types of basic data were obtained, the first from all patients involved in the study (a), and the second measuring other data related to period of the most recent therapeutic regimen (b):

1.  a1. Socio-demographic characteristics (sex, age, level of education, number of inhabitants in the city of residence, social status);

2.  a2. health characteristics (diabetes duration, smoking habits);

3.  b1. frequency of routine self-monitoring of blood glucose (BG) and blood pressure;

4.  b2. incidence of adverse events during treatment (hypoglycemia, adverse reaction at the insulin injection site, problems with use of insulin pump or insulin pen).

The questionnaires are available on request.

Both the CSII and MDI groups of patients were administered the Self-Care Inventory-Revised (SCI-R) (La Greca; 2005)[@b19-ppa-7-867] and the Diabetes Treatment Satisfaction Questionnaire-status version (DTSQs) (Bradley; 1994).[@b20-ppa-7-867] The DTSQs was available in the linguistically validated Czech version which suitability we corroborated with Cronbach's α of 0.86. The SCI-R was translated into Czech and validated with a Cronbach's α of 0.73. To ensure the quality of the SCI-R in Czech, forward-backward translation was performed by two independent translators.

All tools used and the study design were discussed with clinicians. Prior to starting data collection, a pilot study was conducted with ten type 1 diabetes patients.

Data derived from medical records
---------------------------------

1.  Nature and duration of current insulin therapy;

2.  basal and bolus insulin type and usual dose (patients are routinely advised to adjust doses of insulin according to their daily regime and BG level by health care providers);

3.  other prescription medications used;

4.  clinical parameters (height, weight, glycosylated hemoglobin, and blood pressure) based on at least two measurements performed within the last 12 months (including measurements taken on the day the questionnaires were filled out). These measurements were then averaged for each respondent.

Outcome measures
----------------

### Adherence to self-care recommendations (SCI-R)

To evaluate the adherence to self-care recommendations, the SCI-R[@b19-ppa-7-867],[@b21-ppa-7-867] was used. This protocol assesses patients' perceptions of the degree to which they have adhered to the recommendations for their diabetes self-care in the past 1--2 months. The form includes 15 questions that can be categorized into the following groups: BG regulation (two questions); insulin and food regulation (eight questions); exercise (one question), and emergency precautions (three questions). One question is related to routine follow-up visits to the treatment center. Some questions deal with several of these subject areas. The SCI-R answers are scored on a five-point Likert scale (never, rarely, sometimes, usually, always; 1--5 points, respectively). The output of the questionnaire is a numerical score, with a higher score indicating a higher adherence to self-care recommendations. The complete questionnaire and questionnaire manual are available in electronic form.[@b19-ppa-7-867],[@b22-ppa-7-867]

Satisfaction with treatment (DTSQs)
-----------------------------------

The DTSQs[@b20-ppa-7-867] is a specific tool to measure satisfaction with treatment in patients with type 1 and 2 diabetes. It includes eight items, with answers scored from 0 (very dissatisfied) to 6 (very satisfied). The questions are related; for example, for treatment flexibility, the degree of the patient's satisfaction in terms of understanding diabetes as well as the likelihood of the patient recommending the treatment to another person with similar manifestations of the disease. The total score is a sum of six individual item scores. A higher total score indicates a higher satisfaction with treatment. Two questions related to the perceived frequency of hyper- and hypoglycemic events are assessed separately. Patients who indicated an unacceptably high or low BG level most of the time were instructed to mark 6 and those who never experienced such feelings to mark 0. The questionnaire manual is available in electronic form.[@b23-ppa-7-867]

Statistical analysis
--------------------

Statistical analysis was performed using the PASW 18.0 software (version 18.0, IBM Corporation, Armonk, NY, USA). A *P*-value of \< 0.05 was considered statistically significant. Data are summarized as the mean (± standard deviation \[SD\]), median, or range for continuous variables, and percentages for categorical variables. Differences in patient characteristics between the two treatment regimens were compared using the χ^2^ test for categorical variables and the Mann--Whitney *U* test for continuous variables.

To investigate associations with the adherence score (continuous variable), the Mann--Whitney test was used for dichotomous variables and Spearman correlations were used for continuous variables. Multiple linear regression was employed to identify independent variables associated with adherence. All variables with a statistically significant association with the adherence score in the previous analyses were included in the regression analysis. Clinical relevance of the effect was assessed by means of η^2^. The limits between categories were taken from the Cohen convention.[@b24-ppa-7-867]

Results
=======

Characteristics of patients
---------------------------

The socio-demographic characteristics of the study population are presented in [Table 1](#t1-ppa-7-867){ref-type="table"}. Almost no differences in basic socio-demographic characteristics were found between the CSII group and MDI group, save for the finding that MDI patients reported a larger number of inhabitants in the city of residence (*P* \< 0.01).

Clinical characteristics of the study population are summarized in [Table 2](#t2-ppa-7-867){ref-type="table"}. Patients receiving the CSII therapy were more often treated with insulin analogues, with lower bolus and total insulin doses (IU/kg/day), as well as used more boluses during the day (*P* ≤ 0.001 for each factor). At the same time, these patients have a higher average body mass index (BMI) than patients undergoing MDI therapy (*P* \< 0.01). A higher incidence of difficulties with the device for the application of insulin was reported by insulin pump users than by insulin pen users (*P* = 0.011).

Self-monitoring frequency
-------------------------

Patients on CSII therapy performed self-monitoring of fasting BG (*P* \< 0.05) and before meal BG (*P* \< 0.01) more often. The two groups did not differ in the frequency of self-monitoring of other types of BG ([Table 3](#t3-ppa-7-867){ref-type="table"}).

Self-care adherence
-------------------

The patients studied most often failed to comply with the recommendations for keeping food records and checking ketones when their glucose level was high. The highest adherence level was reported by the patients for keeping clinic appointments/having phone contact with the doctor, and taking the correct dose of insulin. The SCI-R mean individual and total scores are given in [Table 4](#t4-ppa-7-867){ref-type="table"}. The adherence scores did not differ between the CSII and MDI patients.

The significant associations between adherence and other variables for the total cohort are summarized in [Table 5](#t5-ppa-7-867){ref-type="table"}. Significant results of the subsequent multiple analyses for the total cohort are shown in [Table 6](#t6-ppa-7-867){ref-type="table"}.

Satisfaction with treatment
---------------------------

The mean DTSQs total score (±SD) of the whole study cohort, CSII group, and MDI group was 29.6 ± 5.3; 30.4 ± 4.0; 28.6 ± 6.4, respectively (36.0 being the maximum possible score). The mean scores for the questions related to the perceived frequency of hyper- and hypoglycemia were 2.3 ± 1.3 and 2.0 ± 1.3; 2.4 ± 1.4 and 2.0 ± 1.2; 2.3 ± 1.3 and 2.1 ± 1.4, respectively (0 = never; 6 = most of the time). The treatment satisfaction scores did not differ significantly between the CSII and MDI patients.

Discussion
==========

To our knowledge, adherence correlates in patients with type 1 diabetes have not yet been studied to an extent as in the present study. Focusing on associations between adherence and a range of various factors, our work showed that adherence to self-care recommendations in adult patients with type 1 diabetes correlated with treatment satisfaction and did not correlate with socio-demographic and clinical characteristics based on observational data taken from routine practice.

The highest rates of adherence were found in the areas of insulin therapy (administration of the correct insulin dose at the right time), keeping routine clinic appointments, and carrying quick-acting sugar. Despite the fact that patients often indicated "usually" or "always" when answering the items related to compliance with correct food portions and eating meals on time, in practice patients generally failed to comply with the recommendations for keeping food records. Patients more often answered "never" or "rarely" when asked about the ketone testing while they were hyperglycemic. Relatively low scores were given by the patients even to the items regarding reading food labels and glucose recording. These results are in accordance with the data reported by La Greca (available online);[@b22-ppa-7-867] our outcomes are not fully comparable, however, since the revised version of the SCI-R questionnaire was used in our study. Ruggiero et al[@b17-ppa-7-867] and Broadbent et al[@b25-ppa-7-867] have reported lower adherence to diet and exercise than to medication in both type 1 and 2 diabetes patients. This conclusion is consistent with the results obtained in the present study. Relatively high scores given to the core questionnaire items may reflect the high quality of education provided to patients in the Diabetes Center which is reflected in their awareness of the importance of adhering to self-care recommendations.

Factors associated with adherence
---------------------------------

One adherence-associated factor seems to be treatment satisfaction. The correlation between these two variables was significant even after adjustment for potential confounders in multiple linear regression. When the score of DTSQs increases by one, the score of SCI-R increases by approximately 0.5. In the context of various diseases (including diabetes), the correlation has also been confirmed by the previously mentioned review by Barbosa et al.[@b11-ppa-7-867] The scores given regarding adherence and treatment satisfaction in the present study almost did not differ between groups of patients engaging in both types of intensive insulin therapy (IIT). From this, it can be inferred that if both types of IIT are available to the patient (see below), he/she is as likely to be satisfied with or adherent to either of them as not to be. Treatment satisfaction in CSII therapy does not seem to be negatively influenced by a higher frequency of self-monitoring of morning fasting and before meal BG. Significant differences between CSII and MDI therapies in type 1 diabetes patients measured by the DTSQs have also not been reported by other studies.[@b26-ppa-7-867],[@b27-ppa-7-867] On the other hand, an extensive case-control study by Dutch authors[@b28-ppa-7-867] has reported different results, ie, a higher treatment satisfaction in patients on CSII therapy. Treatment satisfaction should not be confused with quality of life which is more influenced by the impact of the disease and its treatment on a wide range of areas of patient's life. Quality of life, which has often been reported as poor despite high treatment satisfaction,[@b29-ppa-7-867] was not measured in the present study.

In the total cohort, a highly significant correlation was found between adherence and the frequency of self-monitoring of before meal BG; this was found even after adjustment for potential confounders in multiple linear regression. When the frequency of self-monitoring of before meal BG increases by one per week, the score of SCI-R increases by approximately 0.3. Patients on CSII therapy reported that they performed self-monitoring of before meal BG significantly more often than those on MDI therapy. This finding was confirmed by Hoogma et al,[@b26-ppa-7-867] who compared the frequency of BG self-monitoring under different IIT regimens. Being aware of before meal BG levels is critical to the calculation of bolus insulin dosage for type 1 diabetes patients; on the other hand, patients on CSII therapy likely appreciate that insulin pump therapy allows for more flexibility in lifestyle. To obtain the maximum benefit from the insulin pump, an optimal adherence to self-monitoring of BG is crucial. We found no other study that focused on the correlation between frequency of BG self-monitoring and adherence to self-care recommendations in type 1 diabetes patients.

Factors not correlated with adherence
-------------------------------------

Adherence did not correlate with socio-demographic characteristics, which is somewhat in accordance with a 1991 critical review on diabetes self-management.[@b30-ppa-7-867] In the present study, correlation analysis found no correlation between adherence nor underlying disease control assessed by glycosylated hemoglobin (HbA~1c~). As for type 1 diabetes, it must be pointed out that HbA~1c~ values are significantly influenced not only by adherence to treatment modalities, but also by diabetes duration, psycho-social status and genetic factors.[@b12-ppa-7-867],[@b18-ppa-7-867] In contrast to other chronic diseases,[@b31-ppa-7-867],[@b32-ppa-7-867] adherence in adults with type 1 diabetes did not correlate with adverse events during treatment. This finding is considered as positive and may be a result of the intensive and high-quality education provided to patients of the Diabetes Center. This diabetes education is tailored to individual needs and is repeated as often as required. The emphasis placed on gaining knowledge and skills makes patients aware of the need for the treatment of their disease, and thus promotes adherence to self-care recommendations despite the treatment-associated problems that may arise.

Strengths and limitations of the study
--------------------------------------

A major positive of the present study is that it was conducted under conditions of real clinical practice in a particular Diabetes Center, thus avoiding the influence of the possible variations in the selection of patients for CSII, patient education or treatment modalities. Also, a relatively high number of patients (111) were enrolled in the study, with both types of IIT being evenly represented. The two groups of patients did not differ in most basic demographic and clinical characteristics. The differences in the total daily insulin dose (IU/kg/day) and BMI between the study groups are in accordance with the results of meta-analyses[@b33-ppa-7-867]--[@b35-ppa-7-867] that compared the clinical outcomes of each type of IIT; these differences are due to the nature of the regimens. Patients on insulin pump therapy, which allows for more flexibility in lifestyle, use lower bolus and total daily insulin doses and a higher number of daily boluses. These individuals eat more meals during the day, which may result in a slight weight (BMI) gain, as is often observed when a patient switches to CSII therapy. The higher percentage of patients on CSII with insulin analogues in comparison with MDI also reflects real conditions of clinical practice. The homogeneity of the study cohort is also supported by the fact that it only includes adult patients with type 1 diabetes. Patients on CSII may differ from those on MDI in some psychological characteristics and abilities.[@b36-ppa-7-867] These characteristics make them suitable candidates for a particular type of therapy and, at the same time, may significantly influence their self-care adherence. Nevertheless, patients on CSII and MDI did not significantly differ in adherence or treatment satisfaction, thus the correlates of adherence were assessed in the study cohort as a whole.

Another advantage of the present study was our use of high-quality and validated assessment tools.[@b19-ppa-7-867],[@b20-ppa-7-867] The significant correlation between adherence and frequency of self-monitoring of before meal BG confirms the appropriateness of the adherence questionnaire used in the present study.

A limitation of the present study is that a self-report method was used to evaluate both adherence as well as the frequency of blood glucose self-monitoring. This might have biased the results, eg, due to the tendency of respondents to present themselves in the best possible light (social desirability bias). Self-reports have been widely used in adherence studies as an inexpensive and time saving tool, and when patients are asked about specific activities and the extent to which these are performed, as is the case in the present study,[@b21-ppa-7-867] more reliable results are usually reported.[@b16-ppa-7-867]

Moreover, the present study focused on adherence to self-care recommendations, which is to say not only to drug therapy, for example. When the results were processed the total score was always used despite the fact that results from different areas of adherence to self-care recommendations may relate to other factors. Consequently, this approach to measuring the multifaceted nature of diabetes self-care may not be sensitive enough.[@b16-ppa-7-867] The total score from the adherence assessment scale was used based on the factorial analysis of results, a fact which demonstrated that the scale as a whole has sufficient internal consistency (Cronbach's α 0.73), and does not contain any item which could have been removed to further increase it. Hence, a single-factor model was used in the present study. Moreover, according to Rabiau et al,[@b37-ppa-7-867] non-adherence in one area may be coupled with better adherence to other self-care recommendations (compensatory beliefs). Patients with equal total scores in different adherence assessment tools may vary regarding the extent to which they adhere to various self-care items, and this fact may not influence the results; eg, of the evaluation of adherence correlates. This assumption needs to be tested in more detail.

As indicated above, the present study did not take into account psychiatric comorbidities that may significantly influence adherence.[@b38-ppa-7-867],[@b39-ppa-7-867] Information about psychiatric therapy, if any, was derived from the records of other prescription drugs used, but such comprehensive records were available for only a small proportion of the study patients, thus a more detailed analysis was not feasible. For the same reason, it was not possible to analyze the relationship between chronic complications of diabetes and adherence. The medical records in each respective area were not standard enough to avoid biasing the results.

Similarly to other studies, another source of bias could be in the selective enrolment of patients who were more motivated to adhere to self-care recommendations than those who declined to fill in the questionnaires. Nevertheless, the proportion of patients who declined to participate was low (7%) and as such was unlikely to be a significant limitation.

Recommendations for future studies in this area
-----------------------------------------------

As stated in the preceding section, it would be better to obtain objective data about the adherence or frequency of blood glucose self-monitoring (downloads from the patients' meters, for instance). Further, we would in addition suggest a study of adherence in patients with type 1 diabetes who are being treated with different modalities, as there could be diverse associations resulting from psychological characteristics as well as abilities in which patients may differ. Then again, higher numbers of patients would be required for such studies. Longitudinal data would be necessary to confirm the results of the current study.

Conclusion
==========

The present study showed that self-care adherence is associated with treatment satisfaction in adult patients with type 1 diabetes. We found out a strong correlation between frequency of self-monitoring of before meal BG and adherence. Adherence to self-care recommendations in adults with type 1 diabetes did not correlate with socio-demographic and clinical characteristics or with adverse events. When monitoring self-care adherence in patients with type 1 diabetes, physicians should question patients about their level of treatment satisfaction in order to target possible reasons for non-satisfaction.
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###### 

Socio-demographic characteristics of the study cohort

  Characteristic                                                                             Total cohort (N = 111)   CSII group (N = 59)   MDI group (N = 52)
  ------------------------------------------------------------------------------------------ ------------------------ --------------------- ---------------------
  Age                                                                                        N = 111                  N = 59                N = 52
   (years; mean ± SD; range)                                                                 42.4 ± 13.8; 19--77      42.1 ± 12.6; 19--65   42.8 ± 15.1; 19--77
  Sex                                                                                        N = 111                  N = 59                N = 52
   Male (%)                                                                                  40.5                     44.1                  36.5
   Female (%)                                                                                59.5                     55.9                  63.5
  Education                                                                                  N = 111                  N = 59                N = 52
   Primary and lower secondary (%)                                                           6.3                      6.8                   5.8
   Apprenticeship training (%)                                                               36.9                     40.7                  32.7
   Upper secondary (%)                                                                       41.4                     39.0                  44.2
   Tertiary (%)                                                                              15.3                     13.6                  17.3
  Size of the place of residence by population[\*\*](#tfn1-ppa-7-867){ref-type="table-fn"}   N = 110                  N = 58                N = 52
   10,000 or less (%)                                                                        56.4                     69.0                  42.3
   10,000--50,000 (%)                                                                        15.5                     8.6                   23.1
   50,000--100,000 (%)                                                                       22.7                     20.7                  25.0
   100,000 or more (%)                                                                       5.5                      1.7                   9.6
  Economic status                                                                            N = 109                  N = 58                N = 51
   Student (%)                                                                               5.5                      3.5                   7.8
   Employee (%)                                                                              61.5                     62.1                  60.8
   Old age pensioner (%)                                                                     13.8                     13.8                  13.7
   Disability pensioner (%)                                                                  19.3                     20.7                  17.6
  Living alone                                                                               N = 111                  N = 59                N = 52
   Yes (%)                                                                                   6.3                      1.7                   11.5
   No (%)                                                                                    93.7                     98.3                  88.5

**Note:**

The difference between MDI and CSII group is highly statistically significant (*P* \< 0.01).

**Abbreviations:** N, number of subjects; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections; SD, standard deviation.

###### 

Clinical characteristics of the study cohort

  Clinical parameter                                                                                              Total cohort (N = 111)   CSII group (N = 59)       MDI group (N = 52)
  --------------------------------------------------------------------------------------------------------------- ------------------------ ------------------------- -------------------------
  Diabetes duration                                                                                               N = 110                  N = 59                    N = 51
   (years; mean ± SD; range)                                                                                      19.2 ± 11.1; 2--53       20.27 ± 10.4; 4--53       18.0 ± 12.0; 2--45
  CSII duration                                                                                                   N = 57                   N = 57                    --
   (months; mean ± SD; range)                                                                                     66.4 ± 58.3; 2--53       66.4 ± 58.3; 2--53        --
  Smoking                                                                                                         N = 87                   N = 44                    N = 43
   Nonsmoker (%)                                                                                                  78.2                     77.3                      79.1
   Occasional smoker (%)                                                                                          12.6                     11.4                      14.0
   Regular smoker (%)                                                                                             9.2                      11.4                      7.0
  **Treatment with insulin**                                                                                                                                         
  Type of insulin[\*\*](#tfn6-ppa-7-867){ref-type="table-fn"}                                                     N = 111                  N = 59                    N = 52
   Insulin analogue (%)                                                                                           80.2                     93.2                      65.4
   Human insulin (%)                                                                                              19.8                     6.8                       34.6
  Total insulin dose[\*\*](#tfn6-ppa-7-867){ref-type="table-fn"}                                                  N = 110                  N = 58                    N = 52
   (IU/kg/day; mean ± SD)                                                                                         0.6 ± 0.3                0.6 ± 0.2                 0.7 ± 0.3
  Basal insulin dose                                                                                              N = 110                  N = 58                    N = 52
   (IU/kg/day; mean ± SD)                                                                                         0.3 ± 0.1                0.3 ± 0.1                 0.3 ± 0.1
  Bolus insulin dose[\*\*](#tfn6-ppa-7-867){ref-type="table-fn"}                                                  N = 110                  N = 59                    N = 51
   (IU/kg/day; mean ± SD)                                                                                         0.3 ± 0.2                0.2 ± 0.1                 0.4 ± 0.2
  Number of boluses/day                                                                                           N = 111                  N = 59                    N = 52
   (mean ± SD)                                                                                                    3.4 ± 0.9                3.7 ± 1.2                 3.1 ± 0.3
  Number of concomitant Rx drugs                                                                                  N = 67                   N = 33                    N = 34
   (mean ± SD)                                                                                                    3.2 ± 2.8                3.4 ± 3.0                 3.0 ± 2.8
  Adjusting the doses of insulin according to daily regime and BG level                                           N = 102                  N = 57                    N = 45
   Yes (%)                                                                                                        97.1                     98.2                      95.6
   No (%)                                                                                                         2.9                      1.8                       4.4
  **Biochemical and clinical measures**                                                                                                                              
  HbA~1c~                                                                                                         N = 111                  N = 59                    N = 52
   (mmol/mol; mean ± SD)                                                                                          66.2 ± 15.3              65.5 ± 14.2               67.0 ± 16.5
  BMI[\*\*](#tfn6-ppa-7-867){ref-type="table-fn"}                                                                 N = 109                  N = 59                    N = 50
   (kg/m^2^; mean ± SD)                                                                                           25.4 ± 3.9               26.4 ± 3.8                24.2 ± 3.8
  Blood pressure                                                                                                  N = 109                  N = 57                    N = 52
   (mmhg; mean ± SD)                                                                                              129.0 ± 9.8/77.9 ± 5.7   129.8 ± 10.1/78.4 ± 5.5   128.0 ± 11.7/77.9 ± 5.9
  **Adverse events**                                                                                                                                                 
  Number of hypoglycemic episodes[a](#tfn3-ppa-7-867){ref-type="table-fn"} in the last month (including severe)   N = 104                  N = 56                    N = 48
   (mean ± SD)                                                                                                    3.6 ± 3.2                4.0 ± 2.9                 3.3 ± 3.5
  Severe hypoglycemia[b](#tfn4-ppa-7-867){ref-type="table-fn"} in the last month                                  N = 105                  N = 58                    N = 47
   Yes (%)                                                                                                        6.7                      3.4                       10.6
   No (%)                                                                                                         93.3                     96.6                      89.4
  Adverse reaction at the insulin injection site                                                                  N = 107                  N = 58                    N = 49
   Yes (%)                                                                                                        59.8                     63.8                      55.1
   No (%)                                                                                                         40.2                     36.2                      44.9
  Problems with insulin pump or insulin pen[\*](#tfn5-ppa-7-867){ref-type="table-fn"}                             N = 105                  N = 58                    N = 48
   Yes (%)                                                                                                        48.1                     67.2                      25.0
   No (%)                                                                                                         51.9                     32.8                      75.0

**Notes:**

Blood glucose ≤3.5 mmol/L;

blood glucose ≤2.0 mmol/L;

the difference between MDI and CSII group is statistically significant (*P* \< 0.05);

the difference between MDI and CSII group is highly statistically significant (*P* \< 0.01).

**Abbreviations:** BG, blood glucose; BMI, body mass index; CSII, continuous subcutaneous insulin infusion; HbA~1c~, glycosylated hemoglobin according to International Federation of Clinical Chemistry; MDI, multiple daily injections; N, number of subjects; SD, standard deviation.

###### 

Frequency of routine self-monitoring of blood glucose and blood pressure in the study cohort

  Self-monitored parameter                                            Total cohort (N = 111)   CSII group (N = 59)   MDI group (N = 52)
  ------------------------------------------------------------------- ------------------------ --------------------- --------------------
  Fasting BG/week[\*](#tfn10-ppa-7-867){ref-type="table-fn"}          N = 75                   N = 41                N = 34
  (mean ± SD)                                                         4.4 ± 2.3                4.8 ± 2.0             3.9 ± 2.5
  Before meal BG/week[\*\*](#tfn11-ppa-7-867){ref-type="table-fn"}    N = 77                   N = 43                N = 34
  (mean ± SD)                                                         9.5 ± 8.4                11.5 ± 8.2            7.1 ± 8.1
  After meal BG/week                                                  N = 77                   N = 43                N = 34
  (mean ± SD)                                                         5.9 ± 5.9                6.6 ± 5.5             5.0 ± 6.2
  Before sleep BG/week                                                N = 101                  N = 57                N = 44
  (mean ± SD)                                                         4.2 ± 2.5                4.5 ± 2.4             3.7 ± 2.6
  Between midnight and 4 am BG/month                                  N = 78                   N = 43                N = 35
  (mean ± SD)                                                         3.4 ± 4.0                3.3 ± 2.3             3.4 ± 5.4
  "Small BG profile"[a](#tfn8-ppa-7-867){ref-type="table-fn"}/month   N = 82                   N = 44                N = 38
  (mean ± SD)                                                         4.0 ± 4.4                4.1 ± 3.7             4.0 ± 5.2
  "Big BG profile"[b](#tfn9-ppa-7-867){ref-type="table-fn"}/month     N = 106                  N = 58                N = 48
  (mean ± SD)                                                         3.1 ± 3.5                3.0 ± 2.4             3.2 ± 4.5
  Blood pressure/year                                                 N = 103                  N = 57                N = 46
  (mean ± SD; median)                                                 46.0 ± 132; 12           28.1 ± 58.3; 12       68.1 ± 185.3; 12

**Notes:**

Fasting BG, BG 1-hour after lunch, 1-hour after dinner and before sleep;

fasting BG, BG 1-hour after breakfast, before lunch, 1-hour after lunch, before dinner, 1-hour after dinner and before sleep;

the difference between MDI and CSII group is statistically significant (*P* \< 0.05);

the difference between MDI and CSII group is highly statistically significant (*P* \< 0.01).

**Abbreviations:** BG, blood glucose; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections; N, number of subjects; SD, standard deviation.

###### 

Adherence to treatment according to SCI-R

                                                                Total cohort (N = 111)   CSII (N = 59)   MDI (N = 52)
  ------------------------------------------------------------- ------------------------ --------------- --------------
  SCI-R total score (mean ± SD)                                 57.1 ± 6.7               57.6 ± 6.3      56.5 ± 7.1
  Glucose testing                                               4.2 ± 0.7                4.3 ± 0.7       4.1 ± 0.7
  Glucose recording                                             3.9 ± 1.0                3.9 ± 0.9       3.8 ± 1.0
  Ketone testing                                                2.2 ± 1.3                2.4 ± 1.3       2.1 ± 1.3
  Administering correct insulin dose                            4.6 ± 0.5                4.6 ± 0.5       4.7 ± 0.5
  Administering insulin at right time                           4.5 ± 0.6                4.4 ± 0.6       4.5 ± 0.5
  Correct food portions                                         4.1 ± 0.6                4.1 ± 0.6       4.1 ± 0.7
  Eating meals on time                                          4.1 ± 0.8                4.2 ± 0.9       4.1 ± 0.7
  Keeping food records                                          1.9 ± 1.0                1.9 ± 1.0       1.9 ± 1.0
  Reading food labels                                           3.4 ± 1.2                3.4 ± 1.2       3.4 ± 1.3
  Proper treatment of low blood glucose                         3.7 ± 1.1                3.8 ± 1.0       3.7 ± 1.2
  Carrying quick-acting sugar                                   4.5 ± 1.0                4.6 ± 0.8       4.4 ± 1.1
  Coming in for appointments/phone contact with the physician   4.7 ± 0.8                4.7 ± 0.8       4.7 ± 1.0
  Wearing a medical alert ID                                    4.0 ± 1.5                4.1 ± 1.4       3.8 ± 1.6
  Exercising                                                    3.3 ± 1.1                3.2 ± 1.1       3.3 ± 1.0
  Proper insulin adjustment                                     4.2 ± 0.9                4.3 ± 0.9       4.2 ± 1.0

**Abbreviations:** N, number of subjects; CSII, continuous subcutaneous insulin infusion; MDI, multiple daily injections; SCI-R, Self Care Inventory-Revised (total score range = 15--75; five-point Likert scale: never -- rarely -- sometimes -- usually -- always; 1--5 points); SD, standard deviation; ID, identification.

###### 

Significant associations between adherence (SCI-R score) and other variables for total cohort (N = 111)

  SCI-R score correlated with                      Correlation coefficient Spearman's rho   Significance (*P*-value)
  ------------------------------------------------ ---------------------------------------- --------------------------
  Education                                        0.216                                    0.027
  Satisfaction with treatment (DTSQs score)        0.254                                    0.020
  Frequency of self-monitoring of before meal BG   0.325                                    0.004
  Frequency of self-monitoring of blood pressure   0.200                                    0.047
  Total insulin dose IU/kg/day                     −0.238                                   0.015
  Basal insulin dose IU/kg/day                     −0.214                                   0.029
  Sex                                              --                                       0.021

**Abbreviations:** SCI-R, Self Care Inventory-Revised; DTSQs, Diabetes Treatment and Satisfaction Questionnaire status version; BG, blood glucose.

###### 

Significant associations between adherence and other variables in multiple analysis for the total cohort (N = 111)

  Factors[a](#tfn15-ppa-7-867){ref-type="table-fn"}   Regression coefficient B   Significance (*P*-value)   Effect size (η^2^)
  --------------------------------------------------- -------------------------- -------------------------- -------------------------------------------------
  **Dependent variable: SCI-R score**                                                                       
  Satisfaction with treatment (DTSQs score)           0.495                      0.004                      0.119[b](#tfn16-ppa-7-867){ref-type="table-fn"}
  Frequency of self-monitoring of before meal BG      0.267                      0.003                      0.126[b](#tfn16-ppa-7-867){ref-type="table-fn"}

**Notes:**

All variables included in the model were: education; satisfaction with treatment (DTSQs score); frequency of self-monitoring of before meal blood glucose; frequency of self-monitoring of blood pressure; total insulin dose IU/kg/day; basal insulin dose IU/kg/day; sex;

medium effect size according to the Cohen convention.[@b24-ppa-7-867]

**Abbreviations:** SCI-R, self-care inventory-revised; DTSQs, diabetes treatment and satisfaction questionnaire status version; BG, blood glucose.
